Mengyao Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mengyao Zhu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Ce Bian
Department of Orthodontics, Beijing Stomatological Hospital and School of Stomatology, Capital MedicalUniversity, No.9 Fanjiacun Road, Fengtai District, Beijing, 100070, China
1 shared publicationChengjun Su
Department of Orthodontics, Beijing Stomatological Hospital and School of Stomatology, Capital MedicalUniversity, No.9 Fanjiacun Road, Fengtai District, Beijing, 100070, China
1 shared publication- Lin-Hai Kurahara
Department of Cardiovascular Physiology, Faculty of Medicine, Kagawa University, Kagawa 761-0793, Japan
1 shared publication - Miao Liu
Department of Orthodontics, Beijing Stomatological Hospital and School of Stomatology, Capital MedicalUniversity, No.9 Fanjiacun Road, Fengtai District, Beijing, 100070, China
1 shared publication - Ning Zhang
Department of Orthodontics, School of Stomatology, Capital Medical University, Beijing, China
1 shared publication - Shen Zhao
Department of Endodontics,Beijing Stomatological Hospital, School of Stomatology, Capital Medical University, Beijing,100070, China
1 shared publication
Latest Publications
- 18 September 2026
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 33, 1-30
Therapeutic Effects of WIN55,212-2 on Temporomandibular Joint Osteoarthritis in a Rat Model and Primary Temporomandibular Joint Condylar Chondrocytes
Introduction/Objective: This study investigates the therapeutic potential of the synthetic cannabinoid WIN55,212-2 (WIN55) in temporomandibular joint osteoarthritis (TMJOA), focusing on its capacity to attenuate cartilage degradation and modulate inflammatory pathways, thereby providing preclinical evidence to support future clinical translation. Methods: A monosodium iodoacetate (MIA)-induced TMJOA model was established in rats, followed by WIN55 treatment. Cartilage integrity and subchondral bone structure were evaluated using histological and imaging techniques. Primary condylar chondrocytes were treated with IL-1β and WIN55 to elucidate the underlying inflammatory and molecular mechanisms through transcriptomic and protein-level analyses. Results: WIN55 significantly alleviated cartilage degradation in TMJOA, as evidenced by improved histological scores, preserved proteoglycan content, and maintained subchondral bone architecture. in vitro, WIN55 suppressed IL-1β-induced pro-inflammatory cytokines (e.g., Il-6, Tnf-α) and chemokines (e.g., Ccl2, Ccl5, Cxcl1). Transcriptomic analysis revealed that WIN55 reversed key inflammatory pathways, including TNF and IL-17 signaling, and downregulated IL-1β-induced colony-stimulating factors (Csf1, Csf2, Csf3). Additionally, WIN55 modulated the expression profiles of lncRNAs and circRNAs. Discussion: These findings provide the first comprehensive evidence that WIN55 exerts multi-target anti-inflammatory and chondroprotective effects in the TMJ context. By suppressing chemokine networks, CSF family members, and matrix-degrading enzymes while preserving extracellular matrix homeostasis, WIN55 addresses both inflammatory and degradative processes central to TMJOA pathogenesis. Modulation of non-coding RNAs suggests additional regulatory layers that may be exploited in future therapeutic strategies. Conclusion: WIN55 demonstrates significant therapeutic potential for TMJOA by mitigating cartilage degradation and modulating inflammatory responses. These findings highlight the promise of cannabinoid-based therapies for TMJOA and establish a foundation for subsequent clinical investigation.
- 18 September 2026
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 33, 1-30
Therapeutic Effects of WIN55,212-2 on Temporomandibular Joint Osteoarthritis in a Rat Model and Primary Temporomandibular Joint Condylar Chondrocytes
Introduction/Objective: This study investigates the therapeutic potential of the synthetic cannabinoid WIN55,212-2 (WIN55) in temporomandibular joint osteoarthritis (TMJOA), focusing on its capacity to attenuate cartilage degradation and modulate inflammatory pathways, thereby providing preclinical evidence to support future clinical translation. Methods: A monosodium iodoacetate (MIA)-induced TMJOA model was established in rats, followed by WIN55 treatment. Cartilage integrity and subchondral bone structure were evaluated using histological and imaging techniques. Primary condylar chondrocytes were treated with IL-1β and WIN55 to elucidate the underlying inflammatory and molecular mechanisms through transcriptomic and protein-level analyses. Results: WIN55 significantly alleviated cartilage degradation in TMJOA, as evidenced by improved histological scores, preserved proteoglycan content, and maintained subchondral bone architecture. in vitro, WIN55 suppressed IL-1β-induced pro-inflammatory cytokines (e.g., Il-6, Tnf-α) and chemokines (e.g., Ccl2, Ccl5, Cxcl1). Transcriptomic analysis revealed that WIN55 reversed key inflammatory pathways, including TNF and IL-17 signaling, and downregulated IL-1β-induced colony-stimulating factors (Csf1, Csf2, Csf3). Additionally, WIN55 modulated the expression profiles of lncRNAs and circRNAs. Discussion: These findings provide the first comprehensive evidence that WIN55 exerts multi-target anti-inflammatory and chondroprotective effects in the TMJ context. By suppressing chemokine networks, CSF family members, and matrix-degrading enzymes while preserving extracellular matrix homeostasis, WIN55 addresses both inflammatory and degradative processes central to TMJOA pathogenesis. Modulation of non-coding RNAs suggests additional regulatory layers that may be exploited in future therapeutic strategies. Conclusion: WIN55 demonstrates significant therapeutic potential for TMJOA by mitigating cartilage degradation and modulating inflammatory responses. These findings highlight the promise of cannabinoid-based therapies for TMJOA and establish a foundation for subsequent clinical investigation.